Life-changing therapies

Innovative medicines pipeline
Macrocycle discovery platform
Collaborate with Polyphor

Latest news

• Polyphor to present its antibiotic programs at the American Society of Microbiology (ASM) Microbe 2019 Conference

• Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer

See all news

Meet us at

May 20-22, 2019	UBS Global Healthcare Conference, New York
April 17, 2019	Kempen Life Sciences Conference, Amsterdam

 

Event calendar

Innovative medicines pipeline

Antibiotics

Murepavadin (POL7080) – Pseudomonas infections

Phase III

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

OMPTA platform –  targeting Gram-negative resistant pathogens

Lead preclinical compound: POL7306

 

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

CXCR4 antagonist

Balixafortide (POL6326) – for novel immune-oncology agent for combination therapy

Fast Track Designation granted by FDA

Phase III

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Inhaled elastase inhibitor

POL6014 – Cystic Fibrosis

Outlicensed to Santhera Pharmaceuticals 14.02.2018

Phase I

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Macrocycle discovery platform

New modalities to address challenging biological targets

Learn more